Cadrenal Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 4
- Market Cap
- $429.1K
- Website
- http://www.cadrenal.com
- Introduction
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Cadrenal Therapeutics Advances Towards Phase 3 Trial of Tecarfarin for LVAD Patients
Cadrenal Therapeutics is preparing for a pivotal Phase 3 trial of tecarfarin specifically targeting patients with Left Ventricular Assist Devices (LVADs), addressing an important anticoagulation need in this population.
Cadrenal Therapeutics Partners with Abbott to Advance Novel Anticoagulant Trial for LVAD Patients
Cadrenal Therapeutics and Abbott have formed a strategic collaboration to evaluate tecarfarin, a new oral Vitamin K antagonist, in patients with HeartMate 3 left ventricular assist devices.
Cadrenal Therapeutics Plans Phase 3 Trial for Tecarfarin in LVAD Patients
Cadrenal Therapeutics aims to initiate a Phase 3 clinical trial for tecarfarin in LVAD patients in 2025, following discussions with the FDA.
Tecarfarin Shows Promise in Reducing Bleeding Events in LVAD Patients
Dr. Mandeep Mehra presented data on tecarfarin's potential to improve Time in Therapeutic Range (TTR) in patients with Abbott HeartMate3 LVADs at the EACTS Summit.
Tecarfarin Shows Promise in LVAD Patients with Potential to Improve Anticoagulation
Tecarfarin's data and Cadrenal's trial protocol were presented at the EACTS Mechanical Circulatory Support Summit, focusing on LVAD patients.
Cadrenal Therapeutics Highlights Tecarfarin Data for LVAD Patients at EACTS Summit
Tecarfarin's potential to improve Time in Therapeutic Range (TTR) and reduce bleeding events in HeartMate3 LVAD patients was presented at the EACTS Summit.
Cadrenal Therapeutics' Tecarfarin Advances to Phase 3 for Thrombosis Prevention
Cadrenal Therapeutics is advancing tecarfarin, a novel oral anticoagulant, into a Phase 3 trial for preventing blood clots in patients with left ventricular assist devices (LVADs).